Tempest Therapeutics adjourned its reconvened special meeting to December 11, 2026, lacking votes to approve a charter amendment replacing supermajority voting and allowing written consent. A quorum was present, with 74.64% of outstanding shares.
TPST · Tempest Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, management’s plans have not alleviated the substantial doubt about our ability to continue as a going concern. There is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Latest documents
Tempest Therapeutics adjourned its reconvened special meeting to December 11, 2026, after not having enough votes to approve a charter amendment replacing supermajority voting and allowing stockholder written consent. A quorum of 74.64% of shares was present.
Tempest Therapeutics reported $0.9 million in cash, substantial doubt about continuing as a going concern and expected funding for less than 12 months. It licensed TPST-4903 and secured an equity line of credit of up to $50.0 million.
Tempest reported $0.9 million cash as of September 30, 2026 and substantial doubt about continuing as a going concern, with cash expected to fund operations for less than 12 months. Nasdaq extended its compliance deadline to November 16, 2026.
Tempest Therapeutics exercised its option on November 11, 2026 to license Senlang’s CD7-targeted lentiviral in vivo CAR-T platform worldwide, excluding China, after encouraging preliminary results in 13 relapsed or refractory multiple myeloma patients.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Research
our published analysis of this companyEquibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash used in operating activities | 12.4M | nine months ended September 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TPST
this stock
Tempest Therapeutics, Inc.
|
$6.54M | -88.6% | -54.8% | — | 1.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$135.44B | +17.8% | +46.2% | 34.4 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$99.08B | +24.1% | +20.8% | 21.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.68B | +601.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$64.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 54
Tempest Therapeutics adjourned its reconvened special meeting to December 11, 2026, after not having enough votes to approve a charter amendment replacing supermajority voting and allowing stockholder written consent. A quorum of 74.64% of shares was present.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TPST | -12.5% | -43.2% | -81.1% | -34.0% | -88.6% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | -10.2% | -38.4% | -78.1% | -30.9% | -96.0% |